The study, conducted between 1996 and 2004, enrolled 869 women into the Austrian Breast and Colorectal Cancer Study Group. The patients were randomly split into two groups: one receiving whole breast radiation therapy (with a boost to the tumor bed) plus hormone therapy (either Tamoxifin or Arimidex) after surgery and one receiving only hormone therapy following surgery.
The results show a significant reduction in cancer returning in the breast among the patients who received radiation. Only one relapse in the radiation/hormone therapy group was observed compared with 13 relapses in the hormone therapy only group. Although the radiation therapy helped prevent the breast cancer from returning, researchers found patients in both groups lived just as long and were just as likely to have the cancer spread to other parts of the body.
"The overall survival rate was excellent at 97 percent. Although the overall survival rate for both patients was unchanged, radiation therapy as part of the post-lumpectomy regimen prevents the recurrence of cancer in the breast by almost 100 percent," said Richard Poetter, M.D., lead author of the study and a radiation oncologist at the University Clinic for Radiotherapy and Radiobiology in Vienna, Austria. "It seems that the current standard of care of surgery followed by radiation and hormone therapy is the best treatment for women with early-stage breast cancer."
For more information on radiation therapy for breast cancer, please visit www.rtanswers.org or call 1-800-986-7876 for a free brochure.
If you would like a copy of the abstract, "Lumpectomy Plus Tamoxifen or Arimidex With or Without Whole Breast Irradiation in Women With Favorable Early Breast Cancer," or you would like to speak to the lead author of the study, Richard Poetter, M.D., please call Beth Bukata or Nick Lashinsky October 16-20 in the ASTRO Press Room at the Colorado Convention Center at 303-228-8454 or 303-228-8455. You may also e-mail them at bethb@astro.org or nickl@astro.org.
ASTRO is the largest radiation oncology society in the world, with more than 8,000 members who specialize in treating patients with radiation therapies. As a leading organization in radiation oncology, biology and physics, the Society is dedicated to the advancement of the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research and disseminating research results and representing radiation oncology in a rapidly evolving socioeconomic healthcare environment.